TY - JOUR
T1 - Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis
AU - Lo, Paulisally Hau Yi
AU - Lung, Hong Lok
AU - Cheung, Arthur Kwok Leung
AU - Apte, Suneel S.
AU - Chan, Kwok Wah
AU - Kwong, Fung Mei
AU - Ko, Josephine Mun Yee
AU - Cheng, Yue
AU - Law, Simon
AU - Srivastava, Gopesh
AU - Zabarovsky, Eugene R.
AU - Tsao, Sai Wah
AU - Tang, Johnny Cheuk On
AU - Stanbridge, Eric J.
AU - Lung, Maria Li
N1 - Funding information:
Research Grants Council of the Hong Kong Special Administrative Region, People's Republic of China: grants HKU6617/08M and HKU6415/06M (M.L. Lung); NIH award AR49930 (S.S. Apte); and Swedish Cancer Society, Swedish Research Council, Swedish Institute, Cancer Research Institute in New York/Concern Foundation in Los Angeles, and Karolinska Institute (E.R. Zabarovsky).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Publisher copyright:
©2010 American Association for Cancer Research.
PY - 2010/7/1
Y1 - 2010/7/1
N2 - ADAMTS metalloprotease family member ADAMTS9 maps to 3p14.2 and shows significant associations with the aerodigestive tract cancers esophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma (NPC). However, the functional impact of ADAMTS9 on cancer development has not been explored. In this study, we evaluated the hypothesized antiangiogenic and tumor-suppressive functions of ADAMTS9 in ESCC and NPC, in stringent tumorigenicity and Matrigel plug angiogenesis assays. ADAMTS9 activation suppressed tumor formation in nude mice. Conversely, knockdown of ADAMTS9 resulted in clones reverting to the tumorigenic phenotype of parental cells. In vivo angiogenesis assays revealed a reduction in microvessel numbers in gel plugs injected with tumor-suppressive cell transfectants. Similarly, conditioned medium from cell transfectants dramatically reduced the tube-forming capacity of human umbilical vein endothelial cells. These activities were associated with a reduction in expression levels of the proangiogenic factors MMP9 and VEGFA, which were consistently reduced in ADAMTS9 transfectants derived from both cancers. Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
AB - ADAMTS metalloprotease family member ADAMTS9 maps to 3p14.2 and shows significant associations with the aerodigestive tract cancers esophageal squamous cell carcinoma (ESCC) and nasopharyngeal carcinoma (NPC). However, the functional impact of ADAMTS9 on cancer development has not been explored. In this study, we evaluated the hypothesized antiangiogenic and tumor-suppressive functions of ADAMTS9 in ESCC and NPC, in stringent tumorigenicity and Matrigel plug angiogenesis assays. ADAMTS9 activation suppressed tumor formation in nude mice. Conversely, knockdown of ADAMTS9 resulted in clones reverting to the tumorigenic phenotype of parental cells. In vivo angiogenesis assays revealed a reduction in microvessel numbers in gel plugs injected with tumor-suppressive cell transfectants. Similarly, conditioned medium from cell transfectants dramatically reduced the tube-forming capacity of human umbilical vein endothelial cells. These activities were associated with a reduction in expression levels of the proangiogenic factors MMP9 and VEGFA, which were consistently reduced in ADAMTS9 transfectants derived from both cancers. Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
UR - http://www.scopus.com/inward/record.url?scp=77954352573&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-09-4510
DO - 10.1158/0008-5472.CAN-09-4510
M3 - Journal article
C2 - 20551050
AN - SCOPUS:77954352573
SN - 0008-5472
VL - 70
SP - 5567
EP - 5576
JO - Cancer Research
JF - Cancer Research
IS - 13
ER -